Literature DB >> 10225242

Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States.

E Hilton1, J DeVoti, J L Benach, M L Halluska, D J White, H Paxton, J S Dumler.   

Abstract

PURPOSE: To determine the prevalence of serologic reactivity, the 1-year incidence of seroconversion, and the frequency of multiple infections, and their associations with symptoms in a group of volunteers at high risk for tick-borne infections in New York state.
METHODS: We performed a seroepidemiologic study of Lyme borreliosis, 2 of the ehrlichioses, Rocky Mountain spotted fever, and babesiosis among 671 participants who lived or worked in a high-risk area (mainly in eastern Long Island, New York) for tick-borne diseases. Sera were collected in the winters of 1994 and 1995. Signs and symptoms of tick-borne disease were monitored monthly by mail and telephone. Lyme borreliosis serologies were done by enzyme-linked immunosorbent assay and Western blot. Rocky Mountain spotted fever serologies were initially screened using Dip-S-Ticks, followed by specific indirect immunofluorescence. Ehrlichiosis serologies were determined by epifluorescent microscopy, as were antibodies to Babesia microti.
RESULTS: Of the 671 participants, 88 (13%) had antibodies to > or = 1 tick-borne organisms, including 34 (5% of the total) with antibodies to Borrelia burgdorferi. Twenty-seven participants had evidence of exposure to B. burgdorferi at baseline. Seven participants (1%) seroconverted during the course of the study, 5 of whom were symptomatic for Lyme borreliosis. Antibodies to spotted fever group rickettsiae were seen in 28 participants (4%), 22 of whom were positive at baseline and 6 of whom seroconverted during the observation period. None of the seropositive patients had any symptoms or signs of infection. Twenty-four participants (3%) had serologic evidence of exposure to Ehrlichia (all but one to Ehrlichia equi); 5 (0.7%) seroconverted during the observation period, including 3 subjects who were asymptomatic. Antibodies to B. microti were seen in 7 participants (1%), including one asymptomatic seroconversion during the year of observation. There was evidence of possible dual infection in 5 patients.
CONCLUSION: In a high-risk population, there was evidence of exposure to 5 tick-borne pathogens; however, many infections were asymptomatic, and coinfections were rare.

Entities:  

Mesh:

Year:  1999        PMID: 10225242     DOI: 10.1016/s0002-9343(99)00046-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts.

Authors:  Ana A Weil; Elinor L Baron; Catherine M Brown; Mark S Drapkin
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence.

Authors:  John J Openshaw; David L Swerdlow; John W Krebs; Robert C Holman; Eric Mandel; Alexis Harvey; Dana Haberling; Robert F Massung; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

Review 3.  Coinfections acquired from ixodes ticks.

Authors:  Stephen J Swanson; David Neitzel; Kurt D Reed; Edward A Belongia
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 4.  Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti.

Authors:  David A Leiby
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Advances in Serodiagnostic Testing for Lyme Disease Are at Hand.

Authors:  John A Branda; Barbara A Body; Jeff Boyle; Bernard M Branson; Raymond J Dattwyler; Erol Fikrig; Noel J Gerald; Maria Gomes-Solecki; Martin Kintrup; Michel Ledizet; Andrew E Levin; Michael Lewinski; Lance A Liotta; Adriana Marques; Paul S Mead; Emmanuel F Mongodin; Segaran Pillai; Prasad Rao; William H Robinson; Kristian M Roth; Martin E Schriefer; Thomas Slezak; Jessica Snyder; Allen C Steere; Jan Witkowski; Susan J Wong; Steven E Schutzer
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

6.  Comparison of the Babesia duncani (WA1) IgG detection rates among clinical sera submitted to a reference laboratory for WA1 IgG testing and blood donor specimens from diverse geographic areas of the United States.

Authors:  Harry E Prince; Mary Lapé-Nixon; Hemlata Patel; Cindy Yeh
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

Review 7.  A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease.

Authors:  Gary P Wormser; Franc Strle; Eugene D Shapiro; Raymond J Dattwyler; Paul G Auwaerter
Journal:  Diagn Microbiol Infect Dis       Date:  2016-11-12       Impact factor: 2.803

8.  T2 Magnetic Resonance Assay-Based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole-Blood Samples.

Authors:  Jessica L Snyder; Heidi Giese; Cheryl Bandoski-Gralinski; Jessica Townsend; Beck E Jacobson; Robert Shivers; Anna M Schotthoefer; Thomas R Fritsche; Clayton Green; Steven M Callister; John A Branda; Thomas J Lowery
Journal:  J Clin Microbiol       Date:  2017-05-31       Impact factor: 5.948

9.  Zoonotic infections among employees from Great Smoky Mountains and Rocky Mountain National Parks, 2008-2009.

Authors:  Jennifer Adjemian; Ingrid B Weber; Jennifer McQuiston; Kevin S Griffith; Paul S Mead; William Nicholson; Aubree Roche; Martin Schriefer; Marc Fischer; Olga Kosoy; Janeen J Laven; Robyn A Stoddard; Alex R Hoffmaster; Theresa Smith; Duy Bui; Patricia P Wilkins; Jeffery L Jones; Paige N Gupton; Conrad P Quinn; Nancy Messonnier; Charles Higgins; David Wong
Journal:  Vector Borne Zoonotic Dis       Date:  2012-07-26       Impact factor: 2.133

10.  Immunoproteomic profiling of Rickettsia parkeri and Rickettsia amblyommii.

Authors:  Walairat Pornwiroon; Apichai Bourchookarn; Christopher D Paddock; Kevin R Macaluso
Journal:  Ticks Tick Borne Dis       Date:  2015-07-22       Impact factor: 3.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.